Objective: To compare standardized uptake values (SUV) derived from pre-treatment 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging and clinical prognostic factors in pediatric patients with Hodgkin lymphoma (HL). Methods: Pre-treatment FDG PET/CT findings of 28 children with HL were evaluated in this retrospective study. Metabolic tumor volume (MTV), SUV max normalized by weight (SUV weight ), lean body mass (SUV lbm ), body surface area (SUV bsa ) and plasma glucose levels of tumors (SUV glucose ) were calculated using pre-treatment FDG PET/CT scan images. These metabolic parameters were correlated with clinical factors [age, sex, number of lymph node groups, presence of splenic involvement, bulky mediastinal disease, Ann Arbor stage, serum white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), serum albumin and hemoglobin levels]. Results: SUV bsa , SUV lbm , SUV weight , SUV glucose and MTV were higher in patients with stage III-IV disease, bulky tumor and ≥3 lymph node groups (p<0.05). SUV bsa and SUV glucose were higher in patients with splenic involvement (p<0.05). There was no significant correlation between these metabolic parameters and sex, ESR, levels of albumin and WBC (p>0.05). SUV bsa and SUV lbm were higher in patients with anemia (p<0.05). Additionally, significant increases were detected in SUV weight , MTV, and SUV glucose with increasing age (p=0.005, p=0.027, and p=0.009, respectively). SUV bsa and SUV lbm had no significant correlation with age (p>0.05). Conclusion: Metabolic parameters derived from pre-treatment FDG PET/CT may have an important role in predicting highrisk disease in patients with HL. Also, SUV bsa and SUV lbm may be better markers than SUV weight in the quantitative evaluation of FDG PET/CT scans in pediatric patients.
Introduction
Currently, more than 80% of patients with Hodgkin lymphoma (HL) can be cured by contemporary treatment methods. The present major problem with HL is the long-term complications of treatment. Children who have been treated for HL have a higher risk of developing secondary tumors, cardiac events, and infections (1) . Prognostic factors are considered during treatment planning to decrease the side effects and the likelihood of recurrence or treatment resistance (2) . The most unfavorable prognostic factors according to the International Prognostic Score are stage 4 disease, age ≥45 years, hemoglobin <10.5 g/dl, albumin <4.0 g/dl, white cell count (WBC) ≥15,000/µl, and lymphocyte level <600/ µl or <8%, respectively. Also, presence of B symptoms, high erythrocyte sedimentation rate (ESR), male sex, higher number of involved nodal sites, and bulky-mass tumors are additional factors associated with an increased risk of relapse (3) . It has been reported in many studies that FDG PET-CT is a very useful imaging modality in the primary staging, restaging, assessment of treatment response and evaluation of residual masses of lymphomas (4, 5, 6, 7) . Standardized uptake value (SUV) is used traditionally for the definition of metabolic activity in FDG PET imaging. The patient's body weight is usually employed as the body size measurement during the calculation of SUV. However, lean body mass or body surface area may be preferred for body size measurement by some authors. SUV is also affected by blood glucose level, post-injection uptake time, image resolution, image reconstruction parameters, and volume-of-interestdefinition (8, 9) . Additionally, the maximum SUV (SUV max ) is only measured by the highest image pixel in the tumor regions and doesn't show the metabolic activity of the entire tumor. Metabolic tumor volume (MTV) is another FDG PET/CT parameter, which is the measurement of the tumor volume with increased metabolism. It has been reported that MTV could play an important role in predicting survival in various malignancies (10, 11) . The purpose of this study was to evaluate the role of FDG-PET/CT in staging pediatric HL, and to establish if the metabolic parameters of pre-treatment FDG PET/CT correlated with clinical prognostic factors in pediatric HL patients. If so, metabolic parameters of pre-treatment FDG PET/CT might have a role in predicting treatment failure. Additionally, we evaluated the correlation of age and metabolic parameters in pediatric patients.
Materials and Methods

Patients
Twenty-eight HL patients who underwent pre-treatment FDG PET/CT examinations between May 2009 and December 2014 were included in this retrospective study. Informed consent was waived due to the retrospective nature of the study. Patients older than 18 years were excluded. The study was approved by the Institutional Ethics Committee. The histologic classifications were established according to the standard WHO classification scheme (12) . Results of bone marrow biopsy (BMB), levels of WBC, albumin and hemoglobin values and ESR were recorded. After completion of therapy, patients were The blood glucose levels of patients were confirmed to be less than 180 mg/dL before FDG injection. Low-dose whole-body CT was used for attenuation correction. PET/ CT data were acquired from the top of the skull to the upper thigh.
Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography Analysis
Visual Analyses
Pre-treatment PET/CT images were retrospectively evaluated by two experienced nuclear medicine physicians and one radiologist. The number of lymph node groups was determined. A splenic FDG uptake greater than hepatic uptake was considered as splenic involvement. The marrow was considered as abnormal when the uptake was equal to or greater than that of the liver. Bulky disease was defined as presence of a lymph node mass greater than 0.33 of the maximum intrathoracic cavity width. The intensity of FDG activity within the bone marrow (BM) was evaluated visually. BMB results were used as the gold-standard for staging. The stage of lymphoma was assessed according to the Ann-Arbor classification (13) .
Semi-quantitative Analyses
SUV max and MTV values were obtained from pre-treatment FDG PET/CT images for semi-quantitative evaluation. The SUV max corrected for body weight (SUV weight ) was measured within the hottest tumor lesion according to the formula (14):
The SUV max normalized for lean body mass (SUV lbm ), and body surface area (SUV bsa ) were calculated using the following equations (14) MTV of each hypermetabolic tumor focus was automatically calculated by the software program and MTV of each tumor was summated. The threshold intensity value used in this study was 40% of maximal SUV of each tumor as validated in several previous studies (15, 16) .
Statistical Analyses
The SPSS 20 software was used for statistical analysis.
Comparisons of SUV levels (SUV weight , SUV bsa , SUV lbm , SUV glucose , MTV) and clinical parameters (sex, number of lymph node groups, presence of splenic involvement, bulky disease, Ann Arbor stage, serum levels of albumin, WBC, ESR and hemoglobin) were performed using the independent test or Mann-Whitney U test. All quantitative values are given as mean±standard deviation (SD). Pearson's correlation coefficients were used to evaluate the correlation between PET parameters and age. A statistically significant difference was defined as a p value <0.05.
Results
Patients
The characteristics of the patients are presented in Table 1 . A total of 28 patients with a mean age ±SD of 9.39±4.2 y (male/female: 17/11) were enrolled in this study. Eleven (39.3%) patients had nodular sclerosis subtype and 15 (53.6%) had mixed cellularity subtype. Histologic subtype remained unclassified in two patients. Of all 28 patients, 18 (64.2%) had undergone BMB. The laboratory findings of the patients are summarized in Table 2 . Among all 28 patients, hemoglobin was <10.5 g/dl in nine patients (32.1%), WBC was ≥15000/ml in 11 patients (39.3%), albumin was <4 g/dl in 16 patients Figure 1 ). Only one patient showed positive lymphoma involvement in BMB. There was no increase in BM FDG uptake in 16 of 28 (57.1%) patients. BMB was performed in seven of 16 (43.7%) whose BMB result was negative. Additionally radioluceny and enlargement at the localizations of ischiopubic synchondrosis (IPS) were detected in 4 of the 28 (14.2%) patients. Intense FDG uptakes were seen in these areas (SUV max range 1.17-3.10). These patients didn't suffer from any symptoms such as groin pain and restriction in the movement of the hip joint.
Since these focal FDG uptakes weren't identified in followup PET/CT scans, they were evaluated as the asymmetric ossification pattern of the IPS rather than malignant bone infiltration ( Figure 2 ).
Quantitative Analyses
SUV bsa , SUV lbm , SUV weight , SUV glucose , and MTV values were higher in patients with stage 3-4 disease, a bulky tumor, and ≥3 lymph node groups (p<0.05) ( (8, 9) . Concordant with these reports, our study showed that while SUV weight , MTV and SUV glucose increase with age (p<0.05), SUV bsa and SUV lbm did not significantly correlate with age (p>0.05). Changes with age can reduce the importance of SUV weight , MTV and SUV glucose values as markers to discriminate malignant tumors from benign ones in children. Also, these parameters can be misguiding in evaluating therapy response. SUV lbm and SUV bsa may be preferred in the primary diagnosis, staging and follow up of malignancies in the pediatric population (24) . A diffuse homogeneous BM FDG uptake generally reflects hyperplastic BM caused by severe anemia, use of granulocyte colony stimulating factors, or chemotherapy. However, infiltration of tumor cells can also cause increased diffuse BM FDG uptake. Authors suggest that BMB is the gold standard in the staging of HL (25) . However, focal FDG uptake can be adequate in the diagnosis of bone or BM involvement in HL (13) . Nevertheless, physiologic FDG uptake patterns mimicking bone metastasis such as IPS should be taken into consideration while evaluating PET/CT scans in the pediatric population (26) .
Conclusion
Metabolic parameters derived from pre-treatment FDG PET/ CT scanning can be valuable in predicting high-risk disease in pediatric HL. Also, SUV bsa and SUV lbm might be better 
